Drugs / ASP7317
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03178149 | Jul 2018 → Dec 2027 expected | age-related macular degeneration | Astellas Institute for Regenerative Medicine | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP7317 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03178149 ↗ |
| Action | Restore | “It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD.” NCT03178149 ↗ |
| Modality | Cell therapy | “ASP7317 are human stem cells which have changed into cells found in the retina.” NCT03178149 ↗ |
| Route | Other | “subretinal injection” NCT03178149 ↗ |